Flatiron Health announces 18 research acceptances featuring the company's real-world data to be presented at ISPOR 2026

New research showcases the impact of large language models from extracting nuanced clinical information from unstructured data sources to successfully building digital twin models that simulate patient outcomes under different treatment scenarios

Flatiron Health today announced its presence at the ISPOR—The Professional Society for Health Economics and Outcomes Research Annual Meeting happening from May 17-20, 2026, in Philadelphia, Pennsylvania. Flatiron's high-quality real-world data and innovative research capabilities are featured across 18+ research acceptances, including seven Flatiron authored research posters as well as a panel presentation “Beyond Black Boxes: Transparent, Validated LLM Workflows for Accelerating Global HTA Submissions and Decisions.”

Flatiron’s presence at ISPOR 2026 closely follows the publication of the Validation of Accuracy for LLM/ML-Extracted Information and Data (VALID) Framework in the Journal of Clinical Oncology Clinical Cancer Informatics. The framework represents the first and most comprehensive, peer-reviewed approach to evaluating the quality and reliability of real-world data extracted by large language models and machine learning—establishing new industry standards for data integrity in oncology research.

"The rapid advancements of large language models and AI-enabled tools have required an incredibly thoughtful approach to data validation and research methodologies," said Emily Castellanos, MD, MPH, Senior Medical Director and Head of Research Oncology at Flatiron Health. "Flatiron’s presence at ISPOR reflects our commitment to advancing the field with high-fidelity, decision-ready real world evidence, reinforcing our position as the gold standard in oncology intelligence and a trusted partner for high-stakes clinical and research decisions.”

Research highlights include:

• Research assessing an LLM-approach that integrates PSA and imaging data to derive real-world progression events in prostate cancer with accuracy and completeness
• A study building and evaluating four different digital-twin modeling approaches to predict survival in patients with advanced non-small cell lung cancer
• An application of the newly published VALID framework to assess quality of an LLM-derived prostate cancer real-world dataset
• A collaborative pilot project led by Friends of Cancer Research that demonstrated success of real-world data supported external-control arms depends on the quality of data, consistent methodology, and attentive planning.

Join Flatiron Health at booth #316 Follow Flatiron Health on X and LinkedIn for more updates from #ISPORAnnual.

Speaking Sessions

Abstracts and Poster Presentations

About Flatiron

Flatiron Health is a healthtech company expanding the possibilities for point of care solutions in oncology and using data for good to power smarter care for every person with cancer. Through machine learning and AI, real-world evidence, and breakthroughs in clinical trials, we continue to transform patients’ real-life experiences into knowledge and create a more modern, connected oncology ecosystem. Flatiron Health is an independent affiliate of the Roche Group.

Contact

Nina Toor

press@flatiron.com